Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06935409 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 9, 2026 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Active, Not Recruiting Primary completion date: Jul 31, 2026 to Aug 31, 2026 · Start date changed from estimate of Apr 30, 2025 to Apr 25, 2025 · Site contacts updated at 2 of 2 sitesv2 Show 3 more changesShow less
    • Primary completion date: Jul 31, 2026 to Aug 31, 2026
    • Start date changed from estimate of Apr 30, 2025 to Apr 25, 2025
    • Site contacts updated at 2 of 2 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, controlled, open, multicenter phase III clinical study to evaluate the efficacy and safety of HS-20093 for injection versus gemcitabine in combination with docetaxel in patients with osteosarcoma who have at least second-line treatment failure.
Trial Details
NCT Number NCT06935409
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Osteosarcoma
Enrollment 117 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov